Clinical Evaluation Report (CER) is a regulatory document that presents the systematic collection, appraisal, and analysis of clinical data for a medical device, showing it meets the General Safety and Performance Requirements (GSPRs) of EU MDR 2017/745. The CER is a living record maintained across the device lifecycle.
What is a Clinical Evaluation Report (CER)?
The CER sits at the center of a device’s clinical evidence file. It records how a manufacturer gathered clinical data, judged its relevance and quality, and reached a conclusion about the benefit-risk profile for the stated intended purpose. Article 61 of EU MDR 2017/745 makes clinical evaluation mandatory for every device, from Class I self-certified products to Class III implants, and Annex XIV Part A sets out the method.
The report does not stand alone. It follows a Clinical Evaluation Plan (CEP), which fixes the scope, endpoints, acceptance criteria, and literature search strategy before any data is appraised. Writing a CER without a validated CEP behind it is one of the most common findings in Notified Body review.
Why a Clinical Evaluation Report (CER) matters in medical device development
A weak CER stalls CE marking. Notified Bodies read it as the primary proof that a device is safe and performs as claimed, so gaps translate directly into non-conformities, extra review cycles, and delayed market entry. For a startup burning runway, a rejected technical file can cost quarters.
The stakes are also clinical. The CER ties each safety and performance claim back to evidence and to the risk management file under ISO 14971. If the evidence does not support the intended purpose, the label has to change, or the indication narrows.
Audit exposure runs through the whole lifecycle. Under Article 61(12), clinical evidence must stay current, and for Class IIb and Class III devices, the report is reviewed at least annually. A missing review record is itself a finding, even when nothing needed updating.
How a Clinical Evaluation Report (CER) is built
The process follows a defined, methodologically sound procedure set in Annex XIV Part A. In practice, it moves through several stages:
- Plan (CEP). Define scope, intended purpose, clinical benefits, measurable endpoints, acceptance criteria, the literature search protocol, and any equivalence strategy.
- Identify data. Collect device-specific clinical data: the manufacturer’s own investigations, published literature, and post-market data, including legacy evidence where it remains relevant.
- Appraise. Weigh each source for relevance, methodological quality, and reliability, recording the rationale so a reviewer can follow the logic.
- Analyze. Synthesize the appraised evidence against each relevant GSPR and the intended purpose, then address gaps, alternative treatment options, and residual risks.
- Conclude and maintain. State whether the benefit-risk ratio is acceptable, then feed post-market surveillance and Post-Market Clinical Follow-up (PMCF) results back into the report over time.
The current structural framework comes from guidance document MDCG 2020-13, which Notified Bodies use as the CER assessment template. MEDDEV 2.7/1 Rev. 4 predates the MDR but still guides method, while MDCG 2020-5 and MDCG 2020-6 cover equivalence and sufficient clinical evidence for legacy devices. Clinical investigations that generate new data follow ISO 14155.
Common challenges and best practices
Equivalence is where many reports fail. Claiming another device as equivalent demands a close match on clinical, technical, and biological characteristics, and without a data-sharing agreement, you cannot rely on a competitor’s proprietary data. Teams often overreach here, then lose the claim in review.
Two other patterns recur. First, the CEP is written after the fact to fit data already collected, which reverses the intended logic, and reviewers notice. Second, the literature search is too narrow or poorly documented, so the appraisal cannot be reproduced. A defensible search protocol, with databases, terms, and inclusion criteria stated up front, prevents both.
Good CERs trace every GSPR claim to a specific piece of evidence, keep the language device-specific and indication-specific, and treat the report as a living document rather than a one-time submission. Aligning the CER, the risk file, and the labeling so they tell the same story is what survives an audit.
How SJML helps with Clinical Evaluation Report (CER)
SJML supports clinical evaluation as part of its Compliance-as-a-Service offering. Its QARA teams help build the Clinical Evaluation Plan (CEP), run systematic literature reviews, assess equivalence, and draft the Clinical Evaluation Report (CER) aligned to EU MDR 2017/745 Article 61 and Annex XIV. The same teams plan post-market surveillance and PMCF, maintain traceability from clinical claims back to the GSPRs and the ISO 14971 risk file, and prepare technical documentation for Notified Body review. Support scales from a single report to managed regulatory sustenance across a device portfolio.
Frequently asked questions
Yes. Under Article 61 of the EU MDR 2017/745, every device needs a clinical evaluation, including Class I self-certified products. The depth scales with risk, novelty, and intended use, but even low-risk devices must document clinical evidence in a CER to obtain and keep CE marking.
The Clinical Evaluation Plan (CEP) is the roadmap, written first, that fixes scope, endpoints, acceptance criteria, and search strategy. The Clinical Evaluation Report (CER) is the output that documents the data gathered, its appraisal, and the benefit-risk conclusion. A CER built without a CEP behind it is a frequent review finding.
The CER is a living document. For Class IIb and Class III devices, it must be reviewed at least annually, while lower-risk devices are reviewed on a risk basis. Updates are triggered by new PMCF data, post-market safety signals, design changes, or updated guidance. The review decision must be recorded even when no change is needed.
The CER is a confidential, detailed technical document for the Notified Body and regulators. The Summary of Safety and Clinical Performance (SSCP) is a public-facing summary required for implantable and Class III devices. The SSCP draws on the CER but is written for clinicians and, in part, patients.
The primary basis is EU MDR 2017/745 Article 61 and Annex XIV Part A, with MDCG 2020-13 as the current assessment framework. MEDDEV 2.7/1 Rev. 4 remains a widely used method reference, while MDCG 2020-5 and MDCG 2020-6 address equivalence and clinical evidence for legacy devices.
Related terms
- Clinical Evaluation Plan (CEP)
- Post-Market Clinical Follow-up (PMCF)
- General Safety and Performance Requirements (GSPR)
- Summary of Safety and Clinical Performance (SSCP)
- EU MDR 2017/745
